Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

FOUND: Looking into meridian bioscience s return on capital employed - You Need To See This

According to Benzinga Pro, during Q1, Meridian Bioscience (NASDAQ:VIVO) earned $15.34 million, a 130.43% increase from the preceding quarter. Meridian Bioscience also posted a total of $88.34 million in sales, a 15.93% increase since Q4. Meridian Bioscience earned $6.66 million, and sales totaled $76.20 million in Q4.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.